Biliary tract disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:33:42 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Biliary tract disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Durvalumab with Chemotherapy for Patients with Advanced Biliary Tract Cancer https://clinicaltrials.eu/trial/study-on-durvalumab-with-chemotherapy-for-patients-with-advanced-biliary-tract-cancer/ Fri, 05 Jun 2026 10:50:15 +0000 https://clinicaltrials.eu/trial/study-on-durvalumab-with-chemotherapy-for-patients-with-advanced-biliary-tract-cancer/ This clinical trial is focused on studying the treatment of Advanced Biliary Tract Cancers, which are cancers that occur in the bile ducts, gallbladder, or the area where the bile duct and pancreatic duct meet. The study will use a combination of medications, including Durvalumab (also known as MEDI4736), which is a type of medication that helps the immune system fight cancer, and chemotherapy drugs such as Gemcitabine, Carboplatin, Oxaliplatin, Cisplatin, and Infliximab. These medications are given through an infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of this study is to assess the safety of using Durvalumab in combination with chemotherapy for patients who have not received prior treatment for their advanced biliary tract cancer. Participants in the study will receive these treatments over a period of time, and their health will be monitored closely to observe any effects of the treatment. The study will also include a group of participants who will receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

Throughout the study, participants will undergo regular health check-ups and assessments to monitor their response to the treatment. The study aims to provide valuable information on how well the combination of Durvalumab and chemotherapy works in treating advanced biliary tract cancers and to ensure the safety of the treatment for patients. The study is expected to continue until March 2025, with recruitment having started in September 2023.

]]> Study on Durvalumab and Chemotherapy for Patients with Advanced Biliary Tract Cancer https://clinicaltrials.eu/trial/study-on-durvalumab-and-chemotherapy-for-patients-with-advanced-biliary-tract-cancer/ Thu, 14 May 2026 05:09:25 +0000 https://clinicaltrials.eu/trial/study-on-durvalumab-and-chemotherapy-for-patients-with-advanced-biliary-tract-cancer/ This clinical trial is focused on studying the treatment of Advanced Biliary Tract Cancers, which are cancers that occur in the bile ducts, gallbladder, and the area where the bile duct meets the small intestine. The study will use a medication called Durvalumab, which is a type of drug that helps the immune system fight cancer. Durvalumab will be combined with a chemotherapy treatment that includes Gemcitabine, a drug that helps stop the growth of cancer cells. Other chemotherapy drugs that may be used in combination include Cisplatin, Oxaliplatin, Carboplatin, and Inflectra (infliximab). The purpose of the study is to assess the safety of using Durvalumab with Gemcitabine-based chemotherapy.

Participants in the study will receive the treatment through an infusion, which means the medication will be given directly into a vein. The study will follow a single-arm, open-label design, meaning all participants will receive the same treatment, and both the participants and the researchers will know what treatment is being given. The study will take place over several months, with regular check-ups to monitor the participants’ health and the effects of the treatment. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatment.

The study aims to gather information on how well the treatment works and any side effects that may occur. This information will help doctors understand the potential benefits and risks of using Durvalumab in combination with chemotherapy for treating advanced biliary tract cancers. Participants will be closely monitored throughout the study to ensure their safety and well-being. The study is expected to continue until 2026, with recruitment starting in 2024.

]]>